Put your patients in better control.

CGM First

Greater A1C Improvements

Patients on multiple daily injections (MDI) insulin therapy and CGM saw greater A1C reduction than those on pump therapy and self-monitoring of blood glucose (SMBG).1

Reduction of Hypoglycemia

CGM has been shown to reduce time spent in hypoglycemia by over 50%.2

Driver of Benefits

The COMISAIR study demononstrates that CGM use–not the insulin delivery method–drives A1C reduction. Both MDI patients and those on pump therapy experience significant glycemic benefits when their insulin regimens are augmented by CGM use.1

COMISAIR Study Shows CGM—Not the Delivery System—Drives A1C Reduction<sup>1</sup>

Medicare Coverage for CGM

Medicare now provides coverage for therapeutic CGM systems (those approved for use in making diabetes treatment decisions). The Dexcom G5® CGM System is the first therapeutic CGM system covered as a Medicare benefit.

Information for Patients


Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.


Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34(4):795-800.

Request Dexcom Information for Your Practice

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you have diabetes and are interested in getting started with Dexcom CGM, please contact us here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.